CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-16). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 361 · Search date 2026-07-16 · Methodology v0.6

L. plantarum 299v,
does it really help with Relief of IBS abdominal pain, gas, and bloating?

30-Second Summary
B
Evidence Grade B · 65 · Safety unknown
IBS RCTs exist for strain 299v, but results conflict and cannot be generalized to all probiotics
What the
research shows
Five IBS RCTs specifically testing strain 299v exist, and a 214-person trial reported improvements in abdominal pain and bloating. Positive and null results conflict, however, the studies were generally short, and some key positive evidence was linked to Probi and other industry sources. Certainty is low and the overall rating is B.
What the
ads claim
Marketing can imply that any probiotic helps IBS or transfer 299v findings to every L. plantarum product and every probiotic. This verdict applies only to the exact 299v strain, also designated DSM 9843.
*

Useful facts when choosing a product

  • Products sold in or shipped to Korea may label about 10 billion CFU of LP299V per capsule; whether this is guaranteed through the end of shelf life should be checked.
  • An L. plantarum product that does not specify 299v or DSM 9843 does not share this evidence.
  • Clinical trials generally used about 10 billion CFU daily for four to eight weeks.
  • People with severe illness or immunocompromise should discuss probiotic use with a clinician; this safety issue is separate from the efficacy grade.
Gap Measurement · Verdict 361 · B 65
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Five strain-specific IBS RCTs were identified. Ducrotte 2012 randomized 214 people for four weeks and reported improved abdominal-pain frequency and severity and bloating; the study was supported by the Rosell-Lallemand Institute and Probi AB. Stevenson 2014 found no difference in pain, bloating, or quality of life in an 81-person eight-week RCT. Moeen-Ul-Haq 2022 randomized 120 people and found no significant advantage for pain or bloating. Differences in duration, IBS subtype, and endpoints produce conflicting results and low certainty.

02

Why this is classified as B (65)

Five strain-specific RCTs and a 214-person positive trial support B, while conflicting null results, low certainty, short subjective-outcome studies, and some manufacturer support yield B with 65 points.

Counterpoint. Any benefit may be limited to selected IBS populations and the exact 299v preparation and cannot be transferred to all probiotics.

Rejudgment record. Reassessment (cross-check reflected) — Multiple strain-specific IBS RCTs for 299v, but conflicting positive and null findings, short subjective outcomes, and some Probi links

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
IBS abdominal painBA medium-sized positive RCT coexists with independent null RCTs
GasBSome early trials were positive, but repeated findings and endpoints are inconsistent
BloatingBPositive and null findings conflict and outcomes are largely subjective

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Ducrotte P et al. 2012Randomized double-blind placebo-controlled trial214Supported by the Rosell-Lallemand Institute and Probi ABAbdominal-pain frequency and severity and bloatingPain and bloating improved in the 299v group after four weeks.Key; industry-supported
Stevenson C et al. 2014Randomized double-blind placebo-controlled trial81Partly supported by the Nestle Nutrition Institute Africa and other sourcesAbdominal pain, bloating, and quality of lifeNo significant between-group difference after eight weeks.Key null result
Moeen-Ul-Haq et al. 2022Randomized controlled trial108UnknownAbdominal pain, bloating, and incomplete evacuationNo significant benefit from adding 299v was confirmed.Key null result
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-16).

Ducrotte P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol. 2012;18(30):4012-4018. PMID: 22912552. DOI: 10.3748/wjg.v18.i30.4012.
checked
Stevenson C, Blaauw R, Fredericks E, Visser J, Roux S. Randomized clinical trial: effect of Lactobacillus plantarum 299 v on symptoms of irritable bowel syndrome. Nutrition. 2014;30(10):1151-1157. PMID: 25194614. DOI: 10.1016/j.nut.2014.02.010.
checked
Moeen-Ul-Haq, et al. Role of Lactobacillus plantarum 299v in the management of irritable bowel syndrome. J Pak Med Assoc. 2022;72(3):404-408. PMID: 35320214. DOI: 10.47391/JPMA.0758.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-16 · Corrections: none

Cite this verdict

L. plantarum 299v x IBS abdominal pain, gas, and bloating Evidence Grade B card
[Chamgap] L. plantarum 299v x IBS abdominal pain, gas, and bloating — Evidence Grade B·65. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/gut/lactiplantibacillus-plantarum-299v-ibs/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.